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Small airway fibrosis is the main contributor to physiological airway dysfunction in COPD. One potential mechanism
contributing to small airway fibrosis is epithelial mesenchymal transition (EMT). When associated with angiogenesis
(so called EMT-Type-3) it may well also be the link with the development of airway epithelial cancer, which is
closely associated with COPD and predominantly in large airways. In a recent study published in Respiratory
Research, Reimann and colleagues, showed increased expression of S100A4 in vasculature of human COPD and
murine lungs. It is quite possible that the process of endothelial to mesenchymal transition (EndMT) is active in
COPD lungs which we wish to comment on.
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COPD is mainly caused by smoking, at least in the west-
ern countries and presents with shortness of breath that
is progressively irreversible and associated with an ab-
normal inflammatory response of the airways in re-
sponse to noxious particles and gases [1]. It is a
worldwide health problem and the fourth most common
cause of chronic disability and mortality, even in devel-
oped countries. Unfortunately, the research effort di-
rected into this has been disproportionately weak
compared to its clinical and scientific importance, and
indeed COPD itself is the least researched of all com-
mon chronic conditions compared to its social import-
ance. The term “chronic obstructive pulmonary disease”
(COPD) now widely used, was first introduced into the
literature in 1964 [2]. Later on in the 1970s and 1980s,
sub-phenotypes such as emphysema, chronic bronchitis,
chronic obstructive bronchitis and chronic bronchitis
with emphysema were used [3]. It is a complex disease,
and can have both airway and lung parenchymalCorrespondence: sssohal@utas.edu.au
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tural changes in lung parenchyma, airways, vessels [4].
Remodelling in COPD, may occur in response to
smoking-induced damage to the lungs, but the details of
structural changes and underlying mechanism are poorly
described or understood [4]. One potential mechanism
contributing to small airway fibrosis/obliteration and
epithelial cancers in COPD is epithelial mesenchymal
transition (EMT) [5–9]. Vascular remodelling has also
been widely reported in COPD both in mild to severe
disease but the mechanisms behind, again are poorly
understood [10–13]. Recent study by Reimann and col-
leagues published in Respiratory Research, highlighted
vascular remodelling in COPD with increase in S100A4
expression (or FSP-1, fibroblast specific protein) in vas-
culature of human COPD and murine lungs [14]. Au-
thors discussed the importance of vascular remodelling
in pathophysiology of COPD, however there is no clear
information on how S100A4 might be contributing to
the vascular remodelling in COPD. It is quite possible
that the process of endothelial to mesenchymal transi-
tion (EndMT) is active in COPD lungs (Fig. 1).ributed under the terms of the Creative Commons Attribution 4.0 International
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Fig. 1 Potential contribution of epithelial mesenchymal transition (EMT) and endothelial mesenchymal transition (EndMT) to pathogenies of
COPD and its linkage to lung cancer through formation of pro-cancer stroma
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The classically described process of EMT involves
phenotypic change and migration of epithelial cells into
the sub-epithelial mesenchyme in the lamina propria
(LP) to function as extracellular-matrix producing fibro-
blasts/myofibroblasts [15–19]. EMT is a vital process
during embryogenesis (EMT-Type-I), but can also be
induced as a result of persistent damage and tissue
inflammation [20–22]. There are then two subsequent
outcome possibilities with active EMT: severe and even
complete organ fibrosis (EMT-Type-II), development of
a pre-malignant stroma when associated with angiogen-
esis (EMT-Type-III) [10, 13, 15–22].
We recently published that EMT is an active process
in both small and large airways of COPD patients [5, 8,
9]. Furthermore, the reticular basement membrane
(Rbm) in large airways is hyper-vascular [10] i.e., give
the appearance of active EMT-Type-III, and of course it
is the large airways in COPD, where cancer formation is
common (Fig. 1), especially squamous cell carcinoma
[15, 21, 23]. In small airways no hyper-vascularity of the
Rbm was observed [5], indicating that EMT-Type-II is
active and contributing to small airway fibrosis and ob-
literation at this site, [5, 16–19]. Recently in a random-
ized controlled trial, we also reported that inhaled
corticosteroid fluticasone propionate given over six
months suppressed EMT-related changes in large air-
ways of COPD patients [24]. This was the first study
reporting anti-EMT effects of inhaled corticosteroids in
COPD.
Similar to the process of EMT is endothelial to mesen-
chymal transition (EndMT), in which endothelial cellslose their adhesion properties and apical-basal polarity
to form highly invasive, migratory, spindle-shaped, elon-
gated mesenchymal cells (fibroblasts/myofibroblasts)
and contribute to different pathological processes in the
organism in a number of ways [25]. EndMT is a critical
process during embryogenesis, especially in embryonic
cardiac development [26]. However, in response to per-
sistent damage and inflammation, EndMT can lead to
complete organ fibrosis [27] and cancer as well [25, 27–
30]. In malignancy, it is suggested that myofibroblasts or
cancer associated fibroblasts (CAFs) produced during
EndMT can facilitate tumour growth and cancer pro-
gression, which fits with the underlying pathology as the
tumour tissue is heavily associated with increased angio-
genesis so it is quite possible that vascular endothelial
cells are contributing to the pool of CAFs (Fig. 1) by
transforming into a mesenchymal cell type [28, 30, 31].
EndMT can also initiate the formation of pro-cancer
stroma quite similar to EMT-Type-III, so it has the po-
tential for both, to initiate cancer but at the same time
helps the tumour to thrive [30].
Vascular remodelling has also been reported in COPD,
main structural changes involve intimal and medial
thickening, leading to reduction of lumen diameter and
muscularization of arterioles [32]. The other changes in-
volve hypo-vascular lamina propria and hyper-vascular
Rbm in large airways of smokers and COPD [11, 13, 33–
35]. Both loss of vessels and vascular remodelling give
rise to pulmonary hypertension in COPD [32, 36]. Inter-
estingly, these vascular remodelling changes are also ob-
served in early COPD and in normal lung function
current smokers [11, 13, 14, 32–34, 37]. Reimann and
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in occulated arteries but also in very small vessels with a
diameter of less than 50 μm [14]. Abnormal deposition
of pulmonary smooth like cells has been considered as
the key pathological feature of arterial remodelling [38].
These cells lead to increased production of extracellu-
lar matrix proteins, with deposition of collagen and
elastin proteins contributing to narrowing of arterial
lumen hence pulmonary hypertension. But the origin
of these smooth muscle like cells and the underlying
mechanisms involved in vascular remodelling are
poorly understood [38].
This recent study by Reimann and colleagues brings
some light to this puzzle [14]. The authors observed in-
creased S100A4 expression in the vasculature of both
human COPD and mouse lung. S100A4 is also known as
a fibroblast specific protein – 1 (FSP-1), it is widely re-
ported to be upregulated in fibrosis and cancer in differ-
ent organs and is one of the key proteins which are
upregulated during EMT [8, 39, 40]. We have previously
reported that EMT is an active process in smokers and
COPD with S100A4 as one of the key proteins up-
regulated along with vimentin and others, and contributing
to the fibroblasts and CAFs populations in COPD [5, 8, 9].
Increased S100A4 expression in pulmonary vasculature of
COPD patients suggests that process of endothelium to
mesenchymal transition (EndMT) is also active in COPD in
addition to EMT. It is quite possible that the primary arter-
ial smooth muscle cells staining positively for S100A4 are
the transitioning endothelial cells [38], hence the process of
EndMT is active in COPD contributing to pulmonary vas-
cular remodelling [38]. EndMT might be the mechanism
behind increased expression of S100A4 in COPD. Similar
staining pattern for S100A4 was observed in vessels by our
group as well when we analysed bronchial biopsies and sur-
gically resected lung tissue from smokers and COPD for
EMT related changes [5, 8, 9]. These are important obser-
vations and warrant further studies, as there are no studies
in COPD so far looking for the evidence of active EndMT
but it is quite possible that this process is active.
Conclusions
EMT is likely the process which is contributing to small
airway fibrosis and large airway epithelial cancers. Vas-
cular remodelling is also a key feature of COPD but the
mechanisms behind are poorly understood. In line with
current literature and observations from the recent
study by Reimann and colleagues it is quite possible that
the process of EndMT is active in lungs of COPD pa-
tients. EndMT is possibly contributing to vascular re-
modelling in COPD BUT at the same time is also
potentially contributing to airway fibrosis and malig-
nancy by producing fibroblasts and cancer associated fi-
broblasts (CAFs), this warrants further studies. If this istrue, it will have huge implications for understanding
the underlying pathology of COPD. We believe, that un-
derstanding EMT and EndMT might be the key to un-
derstanding what COPD is really about and its nasty
clinical consequences.
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